度普利尤单抗注射液治疗中重度特应性皮炎的临床疗效

Clinical Effects of Dupilumab Injection in Treating Moderate and Severe Atopic Dermatitis

目的 观察度普利尤单抗注射液对中重度特应性皮炎(Atopic dermatitis, AD)患者采用的临床效果。方法 回顾性分析本院2021年6月至2022年1月间采用度普利尤单抗注射液治疗的65例中重度AD患者的临床资料,所有研究对象均规范治疗4个月,统计分析患者治疗前、治疗2周后、4周后、8周后、12周后以及16周后湿疹面积及严重程度指数(Eczema area and severity index, EASI)、皮肤病生活质量指数(Skin disease quality of life index, DLQI)、瘙痒数值评价标准(Numerical evaluation criteria for pruritus, NRS)和研究者整体评估(Overall investigator assessment, IGA)四项评分,记录患者治疗期间的临床症状改善情况,评价度普利尤单抗对中重度AD对临床治疗效果。结果 65例患者治疗后与治疗前相比,EASI、DLQI、NRS和IGA四项评分具有统计学意义(F=1301.528、400.521、516.176、1106.919,P<0.05),其中治疗16周后的四项评分低于治疗12周后评分,治疗12周后评分低于治疗8周后的评分,治疗8周后评分低于治疗4周后的评分,治疗4周后评分低于治疗2周后的评分,两两比较差异显著(P<0.05)。65例患者在治疗期间均未见明显的皮肤感染、注射部位反应等不良反应,仅2例患者治疗2周内出现以眼部瘙痒不适为主要症状表现的过敏性结膜炎症状,给予抗组胺滴眼液治疗后症状得到有效改善。结论 度普利尤单抗注射液治疗中重度AD患者具有较高的安全性和有效性,可以有效缓解患者的临床症状,减轻其皮损程度,不良反应发生也在可接受范围内,有效促进患者生活质量的提高。

OBJECTIVE To observe the clinical effects of dupilumab injection in treating moderate and severe atopic dermatitis(AD).METHODS Clinical data about 65 moderate and severe AD patients of taking dupilumab injection from June 2021 to January 2022 was retrospectively analyzed.Patients were treated for 4 months.Treatment effects were evaluated through eczema area and severity index(EASI),dermatology life quality index(DLQI),numerical rating scales(NRS) and investigator′s global assessment(IGA) scores before treatment, after 2 w, 4 w, 8 w, 12 w and 16 w of treatment as well as clinical reactions.RESULTS EASI,DLQI,NRS and IGA scores before and after treatment were found to be statistically significant(F=1301.528,400.521,516.176,1106.919;P<0.05);related scores after 16 w were lower than those after 12 w;related scores after 12 w were lower than those after 8 w;related scores after 8 w were lower than those after 4 w;related scores after 4 w were lower than those after 2 w;the differences were statistically significant(P<0.05);during the treatment procedures, no obvious adverse reactions like skin infection and injection site reactions were discovered;within 2 w of treatment, only two cases had allergic conjunctivitis that was manifested by eye itching and discomforts;patients′ symptoms were improved with anti-histamine eye drops.CONCLUSION Dupilumab injection can reduce the clinical symptoms and skin lesions, produce less impact on the adverse reactions, and improve the treatment safety and effectiveness, patient′s life quality.